Lifestyle changes for treating psoriasis

Ko, Shu–Hua; Chi, Ching‐Chi; Yeh, Mei‐Ling; Wang, Shuhui; Tsai, Yu-Shiun; Hsu, Mei-Ya

doi:10.1002/14651858.cd011972.pub2

Cited by 52 publications

(59 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PsO patients also display a baseline airway inflammation that triggers the constellation of chronic respiratory comorbidities, such as asthma and chronic obstructive pulmonary disease (COPD) 3 . Furthermore, PsO patients are frequently smokers and cigarettes increased flares as well as psoriasis severity, predisposing to COPD and exacerbating asthma crisis 4 …”

Section: Introductionmentioning

confidence: 99%

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Damiani

Pacifico

Bragazzi

et al. 2020

Dermatologic Therapy

106

104

View full text Add to dashboard Cite

During COVID-19 outbreak there are discordant opinions toward the impact on biologics in psoriatic (PsO) patients. Thus we performed a single-center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases.We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and five hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to test positive for 3.43 [95% confidence interval (CI) 2.25-5.73], P < .0001), to be self-quarantined at home (OR 9.05 [95% CI 5.61-14.61], P < .0001) and hospitalized (OR 3.59 [95% CI 1.49-8.63], P = .0044), however, not increased risk of ICU admission or death were found. PsO patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm.

show abstract

Section: Introductionmentioning

confidence: 99%

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Damiani

Pacifico

Bragazzi

et al. 2020

Dermatologic Therapy

106

104

View full text Add to dashboard Cite

show abstract

“…Dietary interventions and exercise have been reported to reduce the severity of psoriasis. 2 Increased risks of cardiovascular disease and metabolic syndrome, such as coronary heart disease, hypertension, hypercholesterolemia, and diabetes, 3 , 4 have also been identified in patients with psoriasis, and smoking is a known risk factor for these cardiovascular and metabolic diseases.…”

Section: Introductionmentioning

confidence: 99%

Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis

Zhou

Kong

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective Psoriasis is an immune-mediated chronic inflammatory disease with skin and joint manifestations. Smoking is considered an unfavorable lifestyle factor for psoriasis. We aimed to explore the association between smoking, disease risk, and treatment efficacy in relation to psoriasis. Methods We searched the Cochrane Library, Embase, and PubMed databases for studies examining the relationship between smoking and psoriasis, up to 12 April 2020. We then conducted a meta-analysis using a fixed-effects model to obtain odds ratios (ORs) with 95% confidence intervals (CIs). Results Ever, current, and former smokers all had higher risks of developing psoriasis than non-smokers (pooled ORs (95% CIs): 1.60 (1.51–1.69), 1.63 (1.48–1.80), and 1.36 (1.13–1.64), respectively). Ever smokers were less likely to show disease improvement at 6 months following treatment with biologic agents than non-smokers (pooled OR (95% CI): 0.80 (0.67–0.95)). Conclusions Smoking increases psoriasis risk and negatively impacts the benefits of biologic agents. However, the number of reports is limited and more studies are needed to confirm the effects of smoking and smoking cessation on therapeutic response in patients with psoriasis. Education to encourage a healthy lifestyle remains a valuable approach in clinical practice.

show abstract

“…There is evidence demonstrating that severe psoriasis leads to excess tobacco and alcohol use . There have been no randomised trials examining whether alcohol abstinence and smoking cessation are effective in treating psoriasis …”

Section: Excessive Alcohol and Tobacco Consumptionmentioning

confidence: 99%

Beyond skin deep: addressing comorbidities in psoriasis

Kovitwanichkanont

Chong

Foley

2020

Medical Journal of Australia

View full text Add to dashboard Cite

Summary Psoriasis is a chronic inflammatory disease that is commonly encountered in primary care and is associated with significant morbidity that extends beyond the skin manifestations. Psoriasis is associated with an elevated risk of psoriatic arthritis, cardiovascular disease, obesity, insulin resistance, mental health disorders, certain types of malignancy, inflammatory bowel disease and other immune‐related disorders, and hepatic and renal disease. Enhanced recognition of these comorbidities may lead to earlier diagnosis and potentially better overall health outcomes. Psoriatic nail involvement, severe skin disease and obesity are associated with a greater risk of psoriatic arthritis. Individuals with psoriasis should be routinely screened for psoriatic arthritis to allow for early intervention to improve long term prognosis. Life expectancy is reduced in people with psoriasis due to a variety of causes, with cardiovascular disease and malignancy being the most common aetiologies. Psoriasis affects several factors that contribute to worsened quality of life and increased risk of depression and anxiety. Effective therapies are now available that have been shown to concurrently improve skin disease, quality of life and psychiatric symptoms. As the concordance between psychosocial impact and objective disease severity does not always correlate, it is essential to tailor management strategies specifically to the needs of each individual. Cigarette smoking and excess alcohol consumption are among the most important modifiable risk factors that increase the likelihood of psoriasis development and severity of skin disease. This provides a compelling rationale for smoking cessation and limiting alcohol intake in people with psoriasis beyond their traditional harmful health consequences.

show abstract

Lifestyle changes for treating psoriasis

Cited by 52 publications

References 64 publications

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis

Beyond skin deep: addressing comorbidities in psoriasis

Contact Info

Product

Resources

About